肠道菌群失调与肝细胞癌*

doi:10.3969/j.issn.1672-5069.2016.02.036

摘要/Abstract

摘要： 大量研究表明,肝病,特别是肝硬化和肝癌患者,发生肠道菌群紊乱或细菌过度生长的机率增高,并且肠道菌群失调与肝细胞癌的发生、发展有着密切的联系;肠道菌群所产生的脂多糖（LPS）可与其识别受体Toll样受体4（TLR4）结合,通过细胞内信号转导通路介导一系列免疫炎症反应,进一步加重肝损伤,促进炎症相关的肝细胞癌发生;抗生素可通过调节肠道菌群,减少内毒素的产生等作用有可能减缓肝细胞癌的发生和发展。

关键词: 肝细胞癌, 肠道菌群, 小肠细菌过度生长, 脂多糖, Toll样受体4

Abstract: A tons of studies have shown that the incidence of intestinal disorder or excessive growth of flora is very high in patients with liver diseases,especially with severe liver diseases,such as liver cirrhosis,liver cancer,and there is a close relationship between the intestinal dysbacteriosis and the occurrence of hapatocellular carcinoma. Lipopolysaccharide （LPS） produced by the intestinal flora can bond its recognition receptor-Toll-like receptor 4（TLR4）,through cell internal signaling pathways,mediating a series of immune inflammatory response,leading to furtherliver damages,and promoting inflammation related to the occurrence of hepatocellular carcinoma（HCC）. Antibotics maybe retard the occurrence and development of HCC by regulating intestinal flora or reducing the endotoxin production.

Key words: Hepatocellular carcinoma, Intestinal flora, Small intestinal bacterial overgrowth, Lipopolysaccharide, Toll-like receptor

梁素妨(综述), 许琳(审校). 肠道菌群失调与肝细胞癌^*[J]. 实用肝脏病杂志, 2016, 19(2): 245-248.

Liang Sufang, Xu Lin. Intestinal dysbacteriosis in patients with hapatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 245-248.

参考文献

[1] Dapito DH,Mencin A,Gwak GY,et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.Cancer Cell,2012,21:504-516.
[2] 董永绥. 肠道菌群失调、内毒素与小儿胃肠功能障碍.中国实用儿科杂志,2001,16（1）：5-10.
[3] Vanderpool C,Yan F,Polk DB. Mechanisms of probioticaction:hnplications for therapeutic applications ininflammatory bowel diseases. Inflamm Bowel Dis,2008,14（11）:1585-1596.
[4] 尹军霞,林德荣.肠道菌群与疾病.生物学通报,2004,39（3）：26.
[5] Wigg AJ,Roberts-Thomson IC,Dymock RB,et a1. The role ofsmall intestinal bacterial overgrowth,intestinal permeatility,endotox-aemia,and tumour necrosis factor-a in the pathogensis, Defilippi CL. Deficippi CA,of non-alcoholic steatophepatitis. Gut,2001,48:206-211.
[6] 王为,周国华,冷明芳,等. 酒精性肝病患者小肠细菌过度生长情况研究.中华临床医师杂志,2009,3（11）：86-88.
[7] 张爱军,战淑慧,许琳,等. 肝硬化患者小肠细菌过度生长与肝功能及自发性腹膜炎的关系. 肝脏,2009,14（5）：389-390.
[8] 刘扬,李媛,许琳,等. 小肠细菌过度生长与小肠肿瘤的关系及其临床意义. 世界华人消化杂志,2013,31：3435-3439.
[9] 王为,刘峰,徐爱蕾,等. 三种消化道恶性肿瘤小肠细菌过度生长情况的研究. 医学综述,2011,17 （6）：946-947.
[10] Bustillo I,Larson H,Saif MW. Small intestine bacterial overgrowth:an under-diagnosed cause of diarrhea in patients with pancreatic cancer. J Pancreas,2009,10:576-578.
[11] Sadik R,Abrabamason H,Bjornsson E,et a1. Etiology of portal hypertension may influence gastrointestinal transit. Scand J Gastroenterol,2003,38（10）:1039-1044.
[12] Ramachandran A,Prabhu R,Thomas S,et a1. Intestinal mucosal alterations in experimental cirrhosis in the rat:role of oxygen flee radicals.Hepatology,2002,35（3）:622-629.
[13] 楼俪泓,靖大道. 肝硬化与肠道屏障功能障碍.胃肠病学,2005,10（4）：243-245.
[14] 贾辅忠.肝病与肠道微生态环境. 中国实用内科学杂志,2006,26（13）：971-974.
[15] Schroder J,Wardelmann E,Winkler W,et al. Glutamine dipeptide-supplemented parenteral nutrition reverses gut atrophy, disaccharidase enzyme activity,and absorption in rats. J Parenter Enteral Nutr,1995,19（6）:502-506.
[16] 石刚,陈嘉勇,徐鹏远. 肠道粘膜屏障的损伤与保护.肠外与肠内营养,2004,11（1）：61-63.
[17] Lombardo L,Foti M,Ruggia O,et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol,2010,8:504-508.
[18] Kasravi FB,Wang L,Wang XD,et a1. Bacterial translocationin acute liver injury induced by D-galactosamine. Hepatology, 1996,23（1）:97-103.
[19] 王锦辉,陈旻湖,孙光裕,等.肝硬化患者小肠细菌过度生长与内毒素血症.中华内科杂志,2002,41（7）：459-461.
[20] 刘伟,蒋义斌,钟良,等.慢性肝病小肠细菌过度生长与内毒素血症.中华消化杂志,2005,25（7）：398-400.
[21] 田峰,饶芳,梁少红,等. 微生态制剂联合莫沙必利治疗肝硬化患者内毒素血症的临床研究.中国医药指南,2010,8（24）：98-100.
[22] Hatano E,Tannka A,Iwata S,et a1. Induction of endotoxin tolerance in transgenic mouse liver expressing. Hepatology,1996, 23:669.
[23] 贾淑云,韩德五,马学惠,等. 肝功能衰竭发病机制的研究-肠源性内毒素血症假说. 中华肝脏病杂志,1995,3：80-82.
[24] Shimazu R, Akashi S,Ogata H,et a1. MD-2,a molecule that conferslipopolysaccharide responsiveness on Toll-like receptor. J Exp Med,1999,189（11）:1777-1782.
[25] Strain S,Fesik SW,Armitage IM. Characterization of lipopolysaccharide from a heptoseless mutant of Escherichia coli by carbon 13 nuclear magnetic resonance. J Biol Chem,1983,258（5）:2906-2910.
[26] Paik YH,Schwabe RF, Bataller R,et al. Toll-like receptor 4 mediatesinflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology,2003,37（5）:1043-1055.
[27] Takeda K,Kaisho T,Akira S. Toll-like receptors. Annu Rev Immunol,2003,21:335-376.
[28] 陈圻,邓存良. TLR4在肝脏损伤中的作用研究进展.医学综述,2008,14（19）：2897-2899.
[29] Huang B,Zhao J,Li H,et a1. Toll-like receptors on tumor cells facilitateevasion of immune surveillance. Cancer Res,2005,65（12）:5009-5014.
[30] Schmausser B,Andrulis M,Endrich S,et a1. Toll-like receptorsTLR4,TLR5 and TLR9 on gastric carcinoma cells:an implication for interaction with Helicobacter pylori. Int J Med Microbiol,2005,295（3）:179-185.
[31] Wang L,Liu Q,Sun Q,et a1. TLR4 signaling in cancer cellspromotes chemoattraction of immature dendritic cells via autocrine CCL20. Biochem Biophys Res Commun,2008,366（3）:852-856.
[32] 陈超,张怀强,相磊,等.TLR4在膀胱尿路上皮癌中的表达及意义.山东大学学报：医学版,2009,47（10）：80-82.
[33] Gonzalez Reyes S, Marin L,Gonzalez L,et a1. Study of TLR3,TLR4 and TLR9 in breast carcinomas and their association withmetastasis.BMC Cancer,2010,10（1）:665-667.
[34] Luedde T,Schwabe RF. NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol,2011,8:108-118.
[35] P-lsson-McDermott EM,O’Neill LA. Signal transduction by the lipopolysaccharide receptor,Toll-like receptor-4.Immunology, 2004,113（2）:153-162.
[36] Akira S,Takeda K. Toll-like receptor signaling. Nat Rev Immunol,2004,4（7）:499-511.
[37] Barton GM,Medzhitov R. Toll-like receptor signaling pathways. Science,2003,300（5625）:1524-1525.
[38] Yu LX,Yan HX, Liu Q,et al. Endotoxinaccumulation prevents carcinogen-induced apoptosis and promotes livertumorigenesis in rodents. Hepatology,2010,52:1322-1333.
[39] Wang LL,Zhu R,Huang ZQ,et al. Lipopolysaccharide-induced Toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci,2013,58（8）:2223-2236.

肠道菌群失调与肝细胞癌^*

Intestinal dysbacteriosis in patients with hapatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[2]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[3]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[4]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[5]	张莹, 王洪岩, 迟程, 徐有青. LPS诱导的HepG2细胞NOTCH与LPS-TLR4-NF-κB炎症信号通路的“会话”研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 470-473.
[6]	张璇, 唐小云, 唐春银, 石学魁, 王惠琦, 张晓东, 沈海萍, 杨春辉. 中药方剂赤白汤对D-氨基半乳糖诱导的急性肝衰竭小鼠肠道菌群的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 478-481.
[7]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.
[8]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[9]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[10]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[11]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[12]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[13]	王明,张抒,李明,文君,郑振江. 慢性乙型肝炎患者血清与粪便HBV DNA水平对比研究[J]. 实用肝脏病杂志, 2019, 22(2): 176-179.
[14]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[15]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.